Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer

Precision oncology has fundamentally changed how we diagnose and treat cancer. In recent years, there has been a significant change in the management of patients with oncogene-addicted advanced-stage non-small cell lung cancer (NSCLC). Increasing amounts of identifiable oncogene drivers have led to the development of molecularly targeted drugs. Undoubtedly, the future of thoracic oncology is shifting toward increased molecular testing and the use of targeted therapies. For the most part, these novel drugs have proven to be safe and effective. As with all great innovations, targeted therapies pose unique challenges. Drug toxicities, resistance, access, and costs are some of the expected obstacles that will need to be addressed. This review highlights some of the major in the use of in NSCLC and for the future

Automated summary

Precision oncology has revolutionized cancer diagnosis and treatment. The management of non-small cell lung cancer (NSCLC) has witnessed significant changes with the identification of oncogene drivers and the development of targeted drugs. However, targeted therapies also present unique challenges such as drug toxicities, resistance, access, and costs.